Mass General Brigham Incorporated
Location
Massachusetts
Founded
1994-02-13
Risk Signals
1496 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., General Medical and Surgical Hospitals), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Mass General Brigham Incorporated
Live alerts from global media, monitored by Business Radar
2025-03-27 (bio.org)
Enabling Gene and Cell Therapy translation from bench to clinic at Mass General Brigham's Gene and Cell Therapy Institute (MGB-GCTI) - International Convention 2025
With more than 30 approved gene and cell therapy (GCT) products and the rapid emergence of new GCT technologies, academic medical centers (AMCs) play a crucial role in advancing genetic medicines. However, translating these therapies from bench to clinic requires overcoming numerous challenges, including high costs, complex regulatory pathways, and navigating the translational "valley of death. "To address these challenges, Mass General Brigham's Gene and Cell Therapy Institute (MGB-GCTI) has implemented the RISE model—an institutional framework emphasizing Resource sharing, Interdisciplinary collaboration, Sustainable funding, and Education. In this session speakers will describe the pipeline of latest GCT advancements emerging from academia, including ways AMCs can sustainably incubate GCT development (Dr. Nathan Yozwiak, Head of Research at GCTI).
Read more